ly2334737 and Colonic-Neoplasms

ly2334737 has been researched along with Colonic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for ly2334737 and Colonic-Neoplasms

Article	Year
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22 The design, synthesis, and biological characterization of an orally active prodrug (3) of gemcitabine are described. Additionally, the identification of a novel co-crystal solid form of the compound is presented. Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa. The compound has entered clinical trials and is being evaluated as a potential new anticancer agent. Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Colonic Neoplasms; Crystallization; Crystallography, X-Ray; Cytidine; Deoxycytidine; Gemcitabine; Humans; Mice; Models, Molecular; Molecular Conformation; Prodrugs; Solubility	2009

Article

Year

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22

The design, synthesis, and biological characterization of an orally active prodrug (3) of gemcitabine are described. Additionally, the identification of a novel co-crystal solid form of the compound is presented. Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa. The compound has entered clinical trials and is being evaluated as a potential new anticancer agent.

Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Colonic Neoplasms; Crystallization; Crystallography, X-Ray; Cytidine; Deoxycytidine; Gemcitabine; Humans; Mice; Models, Molecular; Molecular Conformation; Prodrugs; Solubility

2009